These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31475468)

  • 1. Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?
    Luo W; Yang G; Qiu J; Luan J; Zhang Y; You L; Feng M; Zhao F; Liu Y; Cao Z; Zheng L; Zhang T; Zhao Y
    Cancer Med; 2019 Oct; 8(14):6403-6413. PubMed ID: 31475468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
    Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
    Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Binenbaum Y; Na'ara S; Gil Z
    Drug Resist Updat; 2015 Nov; 23():55-68. PubMed ID: 26690340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
    Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
    Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
    Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
    Bhoopathi P; Mannangatti P; Das SK; Fisher PB; Emdad L
    Adv Cancer Res; 2023; 159():285-341. PubMed ID: 37268399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.
    Yao J; An Y; Wie JS; Ji ZL; Lu ZP; Wu JL; Jiang KR; Chen P; Xu ZK; Miao Y
    Swiss Med Wkly; 2011; 141():w13208. PubMed ID: 21630164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.
    Du J; Gu J; Li J
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32677676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
    Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma.
    Panzeri V; Manni I; Capone A; Naro C; Sacconi A; Di Agostino S; de Latouliere L; Montori A; Pilozzi E; Piaggio G; Capurso G; Sette C
    Mol Oncol; 2021 Feb; 15(2):579-595. PubMed ID: 33159833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer.
    Sarvepalli D; Rashid MU; Rahman AU; Ullah W; Hussain I; Hasan B; Jehanzeb S; Khan AK; Jain AG; Khetpal N; Ahmad S
    Crit Rev Oncog; 2019; 24(2):199-212. PubMed ID: 31679214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
    Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV
    Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
    Yoshida K; Toden S; Ravindranathan P; Han H; Goel A
    Carcinogenesis; 2017 Oct; 38(10):1036-1046. PubMed ID: 29048549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.
    Cioffi M; Trabulo SM; Sanchez-Ripoll Y; Miranda-Lorenzo I; Lonardo E; Dorado J; Reis Vieira C; Ramirez JC; Hidalgo M; Aicher A; Hahn S; Sainz B; Heeschen C
    Gut; 2015 Dec; 64(12):1936-48. PubMed ID: 25887381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals.
    Miyabayashi K; Ijichi H; Mohri D; Tada M; Yamamoto K; Asaoka Y; Ikenoue T; Tateishi K; Nakai Y; Isayama H; Morishita Y; Omata M; Moses HL; Koike K
    Cancer Res; 2013 Apr; 73(7):2221-34. PubMed ID: 23378339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
    Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells.
    Trabulo S; Aires A; Aicher A; Heeschen C; Cortajarena AL
    Biochim Biophys Acta Gen Subj; 2017 Jun; 1861(6):1597-1605. PubMed ID: 28161480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity.
    Sharbeen G; Youkhana J; Mawson A; McCarroll J; Nunez A; Biankin A; Johns A; Goldstein D; Phillips P
    Oncotarget; 2017 Feb; 8(6):9216-9229. PubMed ID: 27999205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.